ThermoGenesis Holdings (ThermoGenesis Holdings) Interest Expense : $-7.58 Mil (TTM As of Mar. 2024)

View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ThermoGenesis Holdings's interest expense for the three months ended in Mar. 2024 was $ -1.45 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.58 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ThermoGenesis Holdings's Operating Income for the three months ended in Mar. 2024 was $ -0.56 Mil. ThermoGenesis Holdings's Interest Expense for the three months ended in Mar. 2024 was $ -1.45 Mil. ThermoGenesis Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ThermoGenesis Holdings Interest Expense Historical Data

The historical data trend for ThermoGenesis Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Interest Expense Chart

ThermoGenesis Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.48

-7.91

-6.10

-5.62

-10.03

ThermoGenesis Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-3.90	-0.67	-2.12	-3.34	-1.45

ThermoGenesis Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.58 Mil.

ThermoGenesis Holdings (NAS:THMO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ThermoGenesis Holdings's Interest Expense for the three months ended in Mar. 2024 was $-1.45 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-0.56 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $2.72 Mil.

ThermoGenesis Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

ThermoGenesis Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

ThermoGenesis Holdings (ThermoGenesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (NAS:THMO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

THR:Germany

Address

2711 Citrus Road, Rancho Cordova, CA, USA, 95742

Website

https://www.thermogenesis.com

ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.

Executives

Xiaochun Xu	director	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu	director	2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu	director	2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph	director	MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford	director	7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate	director	350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble	officer: Principal Accounting Officer	2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu	director
Boyalife Investment Inc.	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545